Dermatology · San Antonio, TX
NPI
1497764302
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2829 Babcock Rd, Suite 636
San Antonio, TX, 78229
Phone (210) 615-8460
Groups this clinician bills Medicare through
Medicare paid, 2024
$199K
5,500 services
Medicare patients, 2024
761
Average age 75
Drug cost, 2024
$2.9M
995 prescriptions
Company payments, 2025
$4,789
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ana T Sauceda was code 17003 (destruction skin lesion), 1,698 times for 243 patients. In total Ana T Sauceda billed 5,500 services in 54 codes, and Medicare paid $199K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,698 | 243 | $5.09 | $8,635 |
| 99213 Office E&M - Established | Office | 961 | 524 | $61.57 | $59K |
| 17000 Destruction Skin Lesion | Office | 486 | 307 | $39.95 | $19K |
| 11102 Skin Biopsy | Office | 365 | 282 | $67.64 | $25K |
| 99214 Office E&M - Established | Office | 359 | 205 | $88.80 | $32K |
| 11103 Skin Biopsy | Office | 136 | 90 | $39.38 | $5,356 |
| 99203 Office E&M - New | Office | 104 | 104 | $62.11 | $6,460 |
| 17110 Destruction Skin Lesion | Office | 84 | 66 | $82.61 | $6,939 |
| 99204 Office E&M - New | Office | 41 | 41 | $120.68 | $4,948 |
| 17262 Destruction Skin Lesion | Office | 38 | 29 | $121.13 | $4,603 |
| 17004 Destruction Skin Lesion | Office | 29 | 23 | $128.34 | $3,722 |
| 69100 Other Organ Systems | Office | 17 | 17 | $40.21 | $684 |
| 12032 Wound Repair - All Levels | Office | 17 | 17 | $228.14 | $3,878 |
| 99212 Office E&M - Established | Office | 17 | 16 | $40.86 | $695 |
| 11200 Removal or Shaving of Skin Growth | Office | 13 | 12 | $47.44 | $617 |
By year: 2022 $209K for 5,067 services; 2023 $213K for 5,276 services; 2024 $199K for 5,500 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ana T Sauceda prescribed most often to Medicare patients was Dupixent Pen (Dupilumab), with 192 prescriptions and refills. In total Ana T Sauceda wrote 995 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | 192 | 198 | 31 | $750K |
| Ketoconazole Generic | 76 | 79 | 40 | $1,272 |
| Cosentyx Unoready Pen Secukinumab | 74 | 74 | 13 | $637K |
| Clobetasol Propionate Generic | 56 | 58 | 29 | $2,623 |
| Triamcinolone Acetonide Generic | 51 | 60 | 38 | $620 |
| Hydrocortisone Generic | 49 | 53 | 27 | $388 |
| Otezla Apremilast | 48 | 48 | Under 11 | $232K |
| Doxycycline Hyclate Generic | 30 | 45 | 15 | $1,160 |
| Metronidazole Generic | 27 | 27 | 12 | $1,820 |
| Mupirocin Generic | 25 | 27 | 17 | $294 |
| Taltz Autoinjector Ixekizumab | 22 | 22 | Under 11 | $150K |
| Valacyclovir Valacyclovir Hcl | 21 | 37 | Under 11 | $423 |
| Fluorouracil Generic | 20 | 20 | 17 | $1,324 |
| Clindamycin Phosphate Generic | 19 | 19 | Under 11 | $725 |
| Prednisone Generic | 19 | 41 | 11 | $105 |
Brand drugs: 451 claims; generic drugs: 544 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ana T Sauceda $4,789 ($4,789 in general payments such as food, travel and fees) from 16 companies. The largest payer was Galderma Laboratories, L.P. with $3,361.
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. GALD.SW | 17 | $3,361 |
| Janssen Biotech, Inc. JNJ | 8 | $425 |
| Amgen Inc. AMGN | 3 | $161 |
| Lilly USA, LLC LLY | 3 | $154 |
| Abbvie Inc. ABBV | 8 | $146 |
| Revance Therapeutics, Inc. | 3 | $133 |
| LEO Pharma Inc. | 4 | $98.46 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $81.17 |
| UCB, Inc. UCB.BR | 2 | $57.82 |
| Incyte Corporation INCY | 2 | $53.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.